|
127 Companies |
|
123 Products |
|
123 Products |
|
59 Mechanisms of Action |
|
6 Trials |
|
3245 News |
|
| «12...4142434445464748495051...6566» |
- Enrollment change: Effectiveness of Routine Sterile Gloving in Blood Culture (clinicaltrials.gov) - Dec 2, 2013
P=N/A, N=1854, Completed, Sponsor: Seoul National University Hospital
N=3000 --> 1854
- Trial completion: the DASH Study: Vitamin D and Sexual Health (clinicaltrials.gov) - Dec 2, 2013
P=N/A, N=118, Completed, Sponsor: Ohio State University
N=3000 --> 1854 Active, not recruiting --> Completed
- Trial completion: Surveillance and Follow-up for Latent Tuberculosis Infection and Risk of Developing Active Tuberculosis in Patients Receiving Long-term Dialysis (clinicaltrials.gov) - Dec 2, 2013
P=N/A, N=234, Completed, Sponsor: National Taiwan University Hospital
Active, not recruiting --> Completed Recruiting --> Completed
- Invanz (ertapenem) / Merck (MSD)
Trial initiation date, Head-to-Head: Antibiotics for Klebsiella Liver Abscess Study (clinicaltrials.gov) - Dec 1, 2013
P=N/A, N=152, Recruiting, Sponsor: National University Hospital, Singapore
Recruiting --> Completed Initiation date: Jan 2013 --> Nov 2013
- Invanz (ertapenem) / Merck (MSD)
Enrollment open, Head-to-Head: Antibiotics for Klebsiella Liver Abscess Study (clinicaltrials.gov) - Dec 1, 2013
P=N/A, N=152, Recruiting, Sponsor: National University Hospital, Singapore
Initiation date: Jan 2013 --> Nov 2013 Not yet recruiting --> Recruiting
- drospirenone/ethinyl estradiol / Generic mfg.
Enrollment change: A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS (clinicaltrials.gov) - Dec 1, 2013
P2, N=4, Terminated, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting N=40 --> 4
- | New P1 trial: Phase I Clinical Human Tolerability Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 (clinicaltrials.gov) - Dec 1, 2013
P1, N=24, Completed, Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- levofloxacin / Generic mfg., clarithromycin / Generic mfg.
Enrollment change: Efficacy of High Dose Dual Therapy, Sequential Therapy and Triple Therapy in H. Pylori Eradication (clinicaltrials.gov) - Nov 30, 2013
P4, N=618, Completed, Sponsor: National Taiwan University Hospital
N=40 --> 4 N=800 --> 618
- levofloxacin / Generic mfg., clarithromycin / Generic mfg.
Trial completion: Efficacy of High Dose Dual Therapy, Sequential Therapy and Triple Therapy in H. Pylori Eradication (clinicaltrials.gov) - Nov 30, 2013
P4, N=618, Completed, Sponsor: National Taiwan University Hospital
N=800 --> 618 Recruiting --> Completed
- Sirturo (bedaquiline) / J&J, Pharmstandard
Trial initiation date: A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis (clinicaltrials.gov) - Nov 27, 2013
P3, N=0, Withdrawn, Sponsor: Janssen Infectious Diseases BVBA
Recruiting --> Completed Initiation date: Jan 2013 --> Mar 2014
- Trial completion: PK Study of iOWH032 in Adult Male/Female Healthy Volunteers & Adult Males With Cholera (clinicaltrials.gov) - Nov 25, 2013
P1/2, N=26, Completed, Sponsor: PATH
Initiation date: Jan 2013 --> Mar 2014 Recruiting --> Completed
- ||||| Nimenrix (MenACWY-TT) / Pfizer
New P2 trial: Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers (clinicaltrials.gov) - Nov 24, 2013
P2, N=202, Active, not recruiting, Sponsor: Novartis Vaccines
- Trial completion: Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD (clinicaltrials.gov) - Nov 24, 2013
P=N/A, N=60, Completed, Sponsor: Texas Tech University Health Sciences Center
Recruiting --> Completed Recruiting --> Completed
- Besivance (besifloxacin ophthalmic suspension) / Bausch Health
Enrollment change: Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis (clinicaltrials.gov) - Nov 21, 2013
P3, N=33, Terminated, Sponsor: Bausch & Lomb Incorporated
Recruiting --> Completed N=200 --> 33
- |||||||||| Adacel (tetanus toxoid/reduced diphtheria toxoid/acellular pertussis vaccine adsorbed) / Sanofi
New P3 trial: Sanofi Pasteur's Tdap Combined Vaccine as a Booster Versus Local DT Vaccine in Children or Versus Local Td Vaccine in Adolescents and Adults in China. (clinicaltrials.gov) - Nov 21, 2013
P3, N=1440, Recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
- Trial completion: Efficacy and Safety of an Ethanol/Sodium Citrate Locking Solution: A Pilot Study (clinicaltrials.gov) - Nov 21, 2013
P=N/A, N=40, Completed, Sponsor: University of Manitoba
N=200 --> 33 Active, not recruiting --> Completed
- ||||| New P2 trial: Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180) (clinicaltrials.gov) - Nov 21, 2013
P2, N=480, Recruiting, Sponsor: Novartis Vaccines
- Clinical: XACT: The Utility of Intensified Case Finding Combined With a Package of Novel TB Diagnostics Using a Mobile Clinic in Africa (clinicaltrials.gov) - Nov 19, 2013
P=N/A, N=800, Recruiting, Sponsor: University of Cape Town
- atorvastatin / Generic mfg.
Trial withdrawal: Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial (clinicaltrials.gov) - Nov 19, 2013
P2/3, N=0, Withdrawn, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- atorvastatin / Generic mfg.
Enrollment change: Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial (clinicaltrials.gov) - Nov 19, 2013
P2/3, N=0, Withdrawn, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Not yet recruiting --> Withdrawn N=100 --> 0
- albendazole / Generic mfg., azithromycin / Generic mfg.
Trial initiation date: AZIVAL2: Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis (clinicaltrials.gov) - Nov 18, 2013
P4, N=3680, Not yet recruiting, Sponsor: Emory University
N=100 --> 0 Initiation date: Jul 2013 --> Feb 2014
- |||||||||| Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine) / GSK
New P3 trial: Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese Children (clinicaltrials.gov) - Nov 18, 2013
P3, N=300, Recruiting, Sponsor: GlaxoSmithKline
- ||| NuThrax (AV7909) / Emergent Biosolutions
Enrollment closed, P2 data: A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels (clinicaltrials.gov) - Nov 18, 2013
P2, N=168, Active, not recruiting, Sponsor: Emergent BioSolutions
Initiation date: Jul 2013 --> Feb 2014 Recruiting --> Active, not recruiting
- rifampicin / Generic mfg.
Enrollment closed: Rifampicin Explorative PK Study for Tuberculous Meningitis Comparing Oral and Intravenous Preparation (clinicaltrials.gov) - Nov 17, 2013
P2, N=30, Active, not recruiting, Sponsor: Universitas Padjadjaran
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||||| Daptacel (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) / Sanofi
Trial completion: Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age (clinicaltrials.gov) - Nov 14, 2013
P3, N=3372, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| Baxdela (delafloxacin) / Menarini, Melinta Therap
New P3 trial: Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections (clinicaltrials.gov) - Nov 13, 2013
P3, N=660, Not yet recruiting, Sponsor: Melinta Therapeutics, Inc.
- ||| Trumenba (meningococcal B vaccine) / Pfizer
Enrollment closed: A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents (clinicaltrials.gov) - Nov 13, 2013
P2, N=539, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ceftriaxone / Generic mfg., azithromycin / Generic mfg.
Enrollment change, IO biomarker: Chlamydia Trachomatis Immunology and Vaccinology Study (clinicaltrials.gov) - Nov 13, 2013
P=N/A, N=350, Recruiting, Sponsor: Harold Wiesenfeld
Recruiting --> Active, not recruiting N=240 --> 350
- |||||||||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
New P3 trial: Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination (clinicaltrials.gov) - Nov 12, 2013
P3, N=688, Enrolling by invitation, Sponsor: Sanofi Pasteur, a Sanofi Company
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Trial completion, IO biomarker: A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax (clinicaltrials.gov) - Nov 12, 2013
P3, N=102, Completed, Sponsor: Merck
N=240 --> 350 Active, not recruiting --> Completed
- trimethoprim/sulfamethoxazole / Generic mfg.
Trial initiation date: Pharmacokinetic Parameters of Co-trimoxazole (clinicaltrials.gov) - Nov 11, 2013
P2, N=12, Recruiting, Sponsor: University Medical Centre Groningen
Active, not recruiting --> Completed Initiation date: Jun 2013 --> Oct 2013
- trimethoprim/sulfamethoxazole / Generic mfg.
Enrollment open: Pharmacokinetic Parameters of Co-trimoxazole (clinicaltrials.gov) - Nov 11, 2013
P2, N=12, Recruiting, Sponsor: University Medical Centre Groningen
Initiation date: Jun 2013 --> Oct 2013 Not yet recruiting --> Recruiting
- || Trial suspension: Phase 3, Randomized, Safety, Lot Consistency and Clinical Benefit Study of Recombinant Botulinum Vaccine A/B (clinicaltrials.gov) - Nov 10, 2013
P3, N=6174, Suspended, Sponsor: DynPort Vaccine Company LLC, A CSC Company
Not yet recruiting --> Recruiting Not yet recruiting --> Suspended
- | Trial initiation date: Phase 3, Randomized, Safety, Lot Consistency and Clinical Benefit Study of Recombinant Botulinum Vaccine A/B (clinicaltrials.gov) - Nov 10, 2013
P3, N=6174, Suspended, Sponsor: DynPort Vaccine Company LLC, A CSC Company
Not yet recruiting --> Suspended Initiation date: Oct 2013 --> Oct 2014
- |||| Trial completion: Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose (clinicaltrials.gov) - Nov 10, 2013
P4, N=465, Completed, Sponsor: Novartis Vaccines
Initiation date: Oct 2013 --> Oct 2014 Active, not recruiting --> Completed
- Cdactin-O (CBM-588) / Osel, Miyarisan
Trial withdrawal: Safety and Clinical Effectiveness of Oral Probiotic MIYA-BM to Prevent Recurrent Clostridium Difficile Infections (clinicaltrials.gov) - Nov 7, 2013
P2, N=0, Withdrawn, Sponsor: Osel, Inc.
Active, not recruiting --> Completed Terminated --> Withdrawn
- Enrollment open, Surgery: Fluorometholone as Ancillary Therapy for TT Surgery (clinicaltrials.gov) - Nov 7, 2013
P=N/A, N=156, Recruiting, Sponsor: University of Pennsylvania
Terminated --> Withdrawn Not yet recruiting --> Recruiting
- ||||| Enrollment change: Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1 (clinicaltrials.gov) - Nov 6, 2013
P3, N=805, Completed, Sponsor: Novartis Vaccines
Not yet recruiting --> Recruiting N=1700 --> 805
- Clinical: How Does the Clinical Tool 'What's Going Around' Affect Clinical Practice (clinicaltrials.gov) - Nov 6, 2013
P=N/A, N=15000, Recruiting, Sponsor: NorthShore University HealthSystem
- |||||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
Enrollment open: Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination (clinicaltrials.gov) - Nov 6, 2013
P3, N=688, Enrolling by invitation, Sponsor: Sanofi Pasteur, a Sanofi Company
N=1700 --> 805 Not yet recruiting --> Enrolling by invitation
- Enrollment closed: AIMHi: Testing the Use of Prompts to Increase Adolescent Immunization Rates (clinicaltrials.gov) - Nov 6, 2013
P=N/A, N=7040, Active, not recruiting, Sponsor: University of Rochester
Not yet recruiting --> Enrolling by invitation Not yet recruiting --> Active, not recruiting
- ||||||| Trial completion: Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1 (clinicaltrials.gov) - Nov 6, 2013
P3, N=805, Completed, Sponsor: Novartis Vaccines
Not yet recruiting --> Active, not recruiting Recruiting --> Completed
- Enrollment change, HEOR: HELICOSTIC: Molecular Detection of Antibiotic Resistance and H Pylori Eradication (clinicaltrials.gov) - Nov 6, 2013
P=N/A, N=1386, Completed, Sponsor: Assistance Publique - H
Recruiting --> Completed N=500 --> 1386
- |||||||||| New P3 trial: Phase III Clinical Study of Efficacy and Safety of Vaccae (clinicaltrials.gov) - Nov 6, 2013
P3, N=10000, Recruiting, Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Trial completion, HEOR: HELICOSTIC: Molecular Detection of Antibiotic Resistance and H Pylori Eradication (clinicaltrials.gov) - Nov 6, 2013
P=N/A, N=1386, Completed, Sponsor: Assistance Publique - H
N=500 --> 1386 Recruiting --> Completed
- Cubicin (daptomycin) / Merck (MSD)
New P2b trial: Vancomycin Versus Daptomycin for the Treatment of Methicillin Resistant Staphylococcus Aureus (MRSA) Bacteremia (clinicaltrials.gov) - Nov 3, 2013
P2b, N=50, Recruiting, Sponsor: Singapore General Hospital
- Altabax (retapamulin) / GSK, Almirall
Enrollment open: Retapamulin for Reducing MRSA Nasal Carriage (clinicaltrials.gov) - Nov 3, 2013
P4, N=150, Recruiting, Sponsor: University of California, Irvine
Recruiting --> Completed Not yet recruiting --> Recruiting
- Kineret (anakinra) / SOBI
Enrollment open: Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever (clinicaltrials.gov) - Nov 2, 2013
P3, N=50, Recruiting, Sponsor: Sheba Medical Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||| Solithera (solithromycin) / Melinta Therap, Fujifilm Holdings
Enrollment open: SOLITAIRE-IV: Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia (clinicaltrials.gov) - Oct 31, 2013
P3, N=860, Recruiting, Sponsor: Cempra Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial initiation date: PSARM-S: Community-acquired Methicillin-Resistant Staphylococcus Aureus Carriage Among Athletes (clinicaltrials.gov) - Oct 30, 2013
P=N/A, N=300, Completed, Sponsor: University Hospital, Limoges
Not yet recruiting --> Recruiting Initiation date: Sep 2010 --> Jan 2011